Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classification of malignant lymphoma.

M Uppenkamp1, A C Feller

  • 1Medizinische Klinik A, Klinikum der Stadt Ludwigshafen gGmbH, Germany. Uppenkamm@klilu.de

Onkologie
|February 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]

Der Pathologe·2018
Same author

Chronic Lymphocytic Leukemia (B-CLL) and Immunocytoma (LP-IC): Clinical and Prognostic Relevance of this Distinction.

Leukemia & lymphoma·2016
Same author

Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.

Leukemia·2015
Same author

Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group.

Klinische Padiatrie·2015
Same author

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.

Leukemia·2015
Same author

Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2015

The Revised European American Lymphoma (R.E.A.L.) classification and the subsequent WHO classification provide a unified system for diagnosing hematopoietic and lymphoid neoplasms. These classifications improve diagnostic reproducibility and therapeutic decision-making for hematologists and oncologists.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Historically, diverse lymphoma classifications (Kiel, Working Formulation) hindered international research due to poor correspondence.
  • Previous systems lacked diagnostic reproducibility and a unified approach to comparing clinical trial outcomes across regions.

Purpose of the Study:

  • To introduce the Revised European American Lymphoma (R.E.A.L.) classification, focusing on distinct clinical-pathological entities.
  • To establish a classification system based on cell lineage and differentiation for improved diagnostic accuracy.
  • To highlight the transition to the World Health Organization (WHO) classification, largely based on the R.E.A.L. scheme.

Main Methods:

  • The R.E.A.L. classification abandoned malignancy grading, prioritizing diagnostic reproducibility.

Related Experiment Videos

  • It adopted a cell lineage (T- and B-cell) and differentiation (precursor and mature) based approach.
  • The study outlines the development and principles of the R.E.A.L. and subsequent WHO classification systems.

    • Main Results:

    • The R.E.A.L. classification defined distinct lymphoma entities and improved diagnostic consistency.
    • The WHO classification, closely mirroring the R.E.A.L. scheme, encompasses all hematopoietic and lymphoid neoplasms.
    • This unified approach facilitates better comparison of international research and clinical trial data.

    Conclusions:

    • The R.E.A.L. and WHO classifications represent a significant advancement in lymphoma diagnosis.
    • These systems provide a standardized, reproducible basis for clinical-pathological diagnosis.
    • They offer a solid foundation for therapeutic decisions in hematology and oncology.